Cargando…

The Leukotriene Receptor Antagonist Montelukast Reduces Alpha-Synuclein Load and Restores Memory in an Animal Model of Dementia with Lewy Bodies

Dementia with Lewy bodies (DLB) represents a huge medical need as it accounts for up to 30% of all dementia cases, and there is no cure available. The underyling spectrum of pathology is complex and creates a challenge for targeted molecular therapies. We here tested the hypothesis that leukotrienes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marschallinger, Julia, Altendorfer, Barbara, Rockenstein, Edward, Holztrattner, Miriam, Garnweidner-Raith, Julia, Pillichshammer, Nadine, Leister, Iris, Hutter-Paier, Birgit, Strempfl, Katharina, Unger, Michael S., Chishty, Mansoor, Felder, Thomas, Johnson, Mary, Attems, Johannes, Masliah, Eliezer, Aigner, Ludwig
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609773/ https://www.ncbi.nlm.nih.gov/pubmed/32072462 http://dx.doi.org/10.1007/s13311-020-00836-3

Ejemplares similares

Leukotriene Signaling as a Target in α-Synucleinopathies
por: Strempfl, Katharina, et al.
Publicado: (2022)

The Leukotriene Receptor Antagonist Montelukast Attenuates Neuroinflammation and Affects Cognition in Transgenic 5xFAD Mice
por: Michael, Johanna, et al.
Publicado: (2021)

Improved Bioavailability of Montelukast through a Novel Oral Mucoadhesive Film in Humans and Mice
por: Michael, Johanna, et al.
Publicado: (2020)

The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic
por: Aigner, Ludwig, et al.
Publicado: (2020)

Microglia depletion diminishes key elements of the leukotriene pathway in the brain of Alzheimer’s Disease mice
por: Michael, J., et al.
Publicado: (2020)

Montelukast: More than a Cysteinyl Leukotriene Receptor Antagonist?
por: Tintinger, Gregory R., et al.
Publicado: (2010)

Leukotrienes vs. Montelukast—Activity, Metabolism, and Toxicity Hints for Repurposing
por: Marques, Cátia F., et al.
Publicado: (2022)

Exercise-induced bronchoconstriction: The effects of montelukast, a leukotriene receptor antagonist
por: Kemp, James P
Publicado: (2009)

Time course and progression of wild type α-Synuclein accumulation in a transgenic mouse model
por: Amschl, David, et al.
Publicado: (2013)

Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson’s Disease
por: Wallin, Johan, et al.
Publicado: (2021)

Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity
por: Al-kuraishy, Hayder M., et al.
Publicado: (2021)

APP transgenic modeling of Alzheimer’s disease: mechanisms of neurodegeneration and aberrant neurogenesis
por: Crews, Leslie, et al.
Publicado: (2009)

Montelukast Inhibits Lung Cancer Cell Migration by Suppressing Cysteinyl Leukotriene Receptor 1 Expression In vitro
por: Chen, Yisheng, et al.
Publicado: (2023)

Brain-derived exosomes from dementia with Lewy bodies propagate α-synuclein pathology
por: Ngolab, Jennifer, et al.
Publicado: (2017)

Correction to: Brain-derived exosomes from dementia with Lewy bodies propagate α-synuclein pathology
por: Ngolab, Jennifer, et al.
Publicado: (2020)

Beneficial effects montelukast, cysteinyl-leukotriene receptor antagonist, on renal damage after unilateral ureteral obstruction in rats
por: Otunctemur, Alper, et al.
Publicado: (2015)

Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice
por: Rabl, R., et al.
Publicado: (2017)

Effects of oral cysteine leukotriene receptor antagonist-montelukast on adenoid lymphoid tissue: a histopathological study under light microscope
por: Wang, Zhengying, et al.
Publicado: (2023)

Role of Alterations in Protein Kinase p38γ in the Pathogenesis of the Synaptic Pathology in Dementia With Lewy Bodies and α-Synuclein Transgenic Models
por: Iba, Michiyo, et al.
Publicado: (2020)

Selective Molecular Alterations in the Autophagy Pathway in Patients with Lewy Body Disease and in Models of α-Synucleinopathy
por: Crews, Leslie, et al.
Publicado: (2010)

170 Combination of a Nasal Antihistamine Olopatadine and A Leukotriene Receptor Antagonist Montelukast Sodium for the Treatment of Seasonal Allergic Patients not Currently Controlled on Monotherapy Intranasal Antihistamine or a Leukotriene Receptor Antagonist
por: Nsouli, Safa
Publicado: (2012)

Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson’s disease
por: Valera, Elvira, et al.
Publicado: (2015)

α‐synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease
por: Spencer, Brian, et al.
Publicado: (2016)

Montelukast, a Cysteinyl Leukotriene Receptor 1 Antagonist, Induces M2 Macrophage Polarization and Inhibits Murine Aortic Aneurysm Formation
por: Kawai, Yohei, et al.
Publicado: (2019)

Microglia prevent peripheral immune cell invasion and promote an anti-inflammatory environment in the brain of APP-PS1 transgenic mice
por: Unger, M. S., et al.
Publicado: (2018)

Effects of Novel Calpain Inhibitors in Transgenic Animal Model of Parkinson’s disease/dementia with Lewy bodies
por: Hassen, Getaw Worku, et al.
Publicado: (2018)

Distinct mechanisms of axonal globule formation in mice expressing human wild type α-synuclein or dementia with Lewy bodies-linked P123H ß-synuclein
por: Sekigawa, Akio, et al.
Publicado: (2012)

Cognitive Effects of Montelukast: A Pharmaco-EEG Study
por: Schwimmbeck, Fabian, et al.
Publicado: (2021)

Leukotriene signaling as molecular correlate for cognitive heterogeneity in aging: an exploratory study
por: Mrowetz, Heike, et al.
Publicado: (2023)

The effect of montelukast, a leukotriene receptor antagonist, on the acetic acid-induced model of colitis in rats: Involvement of NO-cGMP-K(ATP) channels pathway
por: Ghorbanzadeh, Behnam, et al.
Publicado: (2022)

Role of Leukotrienes and Leukotriene Modifiers in Asthma
por: Montuschi, Paolo
Publicado: (2010)

Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson’s Disease/Dementia with Lewy Bodies
por: Price, Diana L., et al.
Publicado: (2016)

A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy
por: Spencer, Brian, et al.
Publicado: (2015)

A possible effect of montelukast on neurological aging examined by the use of register data
por: Grinde, Bjørn, et al.
Publicado: (2020)

Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5 – implications for dementia with Lewy bodies
por: Overk, Cassia R, et al.
Publicado: (2014)

Deficiency of terminal complement pathway inhibitor promotes neuronal tau pathology and degeneration in mice
por: Britschgi, Markus, et al.
Publicado: (2012)

Leukotriene Receptor Antagonist, Montelukast Ameliorates L-NAME-Induced Pre-eclampsia in Rats through Suppressing the IL-6/Jak2/STAT3 Signaling Pathway
por: Abdelzaher, Walaa Yehia, et al.
Publicado: (2022)

Correlation of pyroglutamate amyloid β and ptau Ser202/Thr205 levels in Alzheimer’s disease and related murine models
por: Neddens, Joerg, et al.
Publicado: (2020)

Peptides of Presenilin-1 Bind the Amyloid Precursor Protein Ectodomain and Offer a Novel and Specific Therapeutic Approach to Reduce ß-Amyloid in Alzheimer’s Disease
por: Dewji, Nazneen N., et al.
Publicado: (2015)

The Temporal Expression Pattern of Alpha-Synuclein Modulates Olfactory Neurogenesis in Transgenic Mice
por: Schreglmann, Sebastian R., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1lls7qva6e6rikrgggm3hnrs47